Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ · Health Care · market cap 113.59B
Share price
$553.15
At the last nightly close
Intrinsic value
$209.79
A single conservative estimate.
Margin of safety
-62.1%
($209.79 − $553.15) ÷ $553.15
EV / EBIT
1133.2
On the median operating profit of 15 fiscal years through 2025.
How these numbers are computed
The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above starts from the lower of the first two; the Graham Number never enters it.
The frame gives no credit for growth unless the company has earned it: only a return on invested capital that has beaten the cost of capital year after year earns a growth credit, and that credit is capped. A company that compounds will therefore usually read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.
The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.
Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-09-03.
Key metrics
Market position
Annual financials
| Period | Revenue | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|
| 2025-FY | 12.00B | 4.55B | 3.95B | 15.46 | 3.19B |
| 2024-FY | 11.02B | -233.4M | -535.6M | -2.08 | -978.0M |
| 2023-FY | 9.87B | 3.78B | 3.62B | 14.05 | 3.28B |
| 2022-FY | 8.93B | 4.25B | 3.32B | 12.97 | 3.93B |
| 2021-FY | 7.57B | 2.78B | 2.34B | 9.01 | 2.41B |
Filed figures from SEC EDGAR, in the reporting currency.
Recent news
- Vertex Pharmaceuticals (VRTX) Earnings: Latest Report, Earnings Call & Financialspublic.com
- Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?finance.yahoo.com
- Vertex Pharmaceuticals Stock Price | VRTX Stock Quote, News, and History | Markets Insidermarkets.businessinsider.com
- Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectationsstockstory.org
- Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
Headlines link to their source. Sperio does not republish article text.
The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on VRTX.
Run the board on VRTX10 free analyses · no signup, no card
This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.